Patents by Inventor Tilman Schlothauer
Tilman Schlothauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220119482Abstract: Herein is reported a method for producing C-terminally biotinylated FcRn comprising the steps of cultivating a mammalian cell comprising a deoxyribonucleic acid encoding FcRn and E. coli biotin-[acetyl-CoA-carboxylase] ligase (BirA) in a biotin containing medium, and recovering C-terminally biotinylated FcRn from the cell or the cultivation medium, wherein the deoxyribonucleic acid encoding FcRn and E. coli BirA is stably integrated into the genome of the mammalian cell and comprises in 5?- to 3?-direction a first expression cassette encoding class I major histocompatibility complex-like protein (?-FcRn) comprising a HisAvi-tag at the C-terminus, a second expression cassette encoding ?2-microglobulin (?2m), a third expression cassette encoding class I major histocompatibility complex-like protein (?-FcRn) comprising a HisAvi-tag at the C-terminus, a fourth expression cassette encoding ?2-microglobulin (?2m), and a fifth expression cassette encoding E. coli biotin-[acetyl-CoA-carboxylase] ligase.Type: ApplicationFiled: September 30, 2021Publication date: April 21, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Tilman Schlothauer, Stefan Seeber, Jasmin Maria Wehrstein
-
Publication number: 20220099680Abstract: Herein is reported a heterodimeric fusion polypeptide comprising a first proteinaceous moiety and a second proteinaceous moiety, wherein the first proteinaceous moiety and the second proteinaceous moiety are the first and the second antigen of a bispecific antibody which comprises a first binding site that specifically binds to the first proteinaceous moiety and a second binding site that specifically binds to the second proteinaceous moiety, wherein the first proteinaceous moiety is fused to the N-terminus of a first antibody heavy chain Fc-region polypeptide of the IgG1 subtype, wherein the second proteinaceous moiety is fused to the N-terminus of a second antibody heavy chain Fc-region polypeptide of the IgG1 subtype, wherein the first and the second heavy chain Fc-region polypeptide form a disulfide-linked heterodimer, wherein one or both of the heavy chain Fc-region polypeptides comprise a tag for immobilization to a solid phase at its C-terminus, and wherein the first and the second Fc-region polypeptidType: ApplicationFiled: September 29, 2021Publication date: March 31, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Diana Angela PIPPIG, Tilman SCHLOTHAUER, Stefan SEEBER, Adrian ZWICK
-
Patent number: 11286300Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.Type: GrantFiled: September 30, 2016Date of Patent: March 29, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
-
Publication number: 20220073593Abstract: Herein is reported a method for providing a modified antibody with improved in vivo half-live, comprising the modification of the Fc-region of the antibody by introducing one or more mutations that change the binding of the Fc-region to human FcRn until the (relative) retention time of the modified antibody in an FcRn affinity chromatography is increased for more than 1 minute but not more than 5 minutes compared to the parent antibody.Type: ApplicationFiled: April 22, 2021Publication date: March 10, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Thomas EMRICH, Hubert KETTENBERGER, Thomas KRAFT, Wolfgang RICHTER, Tilman SCHLOTHAUER
-
Publication number: 20210395355Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.Type: ApplicationFiled: July 12, 2021Publication date: December 23, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Guido Hartmann, Joerg Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
-
Publication number: 20210325385Abstract: Herein is reported a method for determining the dissociation rate constant kd of an antibody from its antigen at the dissociation pH-value, wherein the method comprises the steps of immobilizing at a first pH-value the antibody on a solid phase to which the antigen of the antibody has been conjugated; applying a pH-gradient from the first pH-value to the dissociation pH-value and thereafter maintaining the pH-value at said dissociation pH-value; and recording the binding signal during the maintaining of the pH-value and calculating therefrom the dissociation rate constant kd of the antibody from its antigen at the dissociation pH-value.Type: ApplicationFiled: June 29, 2021Publication date: October 21, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Tilman Schlothauer, Christian Spick
-
Patent number: 11130810Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: GrantFiled: March 27, 2019Date of Patent: September 28, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
-
Patent number: 11091541Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.Type: GrantFiled: October 29, 2015Date of Patent: August 17, 2021Assignee: HOFFMANN-LA ROCHE INC.Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
-
Publication number: 20210246228Abstract: Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the secondType: ApplicationFiled: December 18, 2020Publication date: August 12, 2021Applicant: Hoffmann-La Roche Inc.Inventor: Tilman Schlothauer
-
Publication number: 20210188960Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: ApplicationFiled: December 16, 2020Publication date: June 24, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
-
Publication number: 20210190795Abstract: Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.Type: ApplicationFiled: January 26, 2021Publication date: June 24, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Thomas Emrich, Hubert Kettenberger, Tilman Schlothauer, Angela Schoch
-
Publication number: 20210139603Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.Type: ApplicationFiled: August 19, 2020Publication date: May 13, 2021Applicant: Roche GlycArt AGInventors: Monika BAEHNER, Stefan JENEWEIN, Manfred KUBBIES, Ekkehard MOESSNER, Tilman SCHLOTHAUER
-
Publication number: 20210139571Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: September 17, 2020Publication date: May 13, 2021Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20210041163Abstract: Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain variable domain (numbering according to Kabat), at positions 55-83 in the light chain variable domain (numbering according to Kabat), at positions 145-174 in the first heavy chain constant domain (numbering according to EU index) and at positions 180-97 in the first heavy chain constant domain (numbering according to EU index), b) determining the binding strength of each of the full length antibodies from the 10 plurality of antibodies to the human neonatal Fc receptor (FcRn), and c) selecting a full length antibody from the plurality of full length antibodies that has a different binding strength to the FcRn than the parent full length antibody.Type: ApplicationFiled: July 27, 2020Publication date: February 11, 2021Inventors: Hubert KETTENBERG, Maximiliane KOENIG, Tilman SCHLOTHAUER, Pernille FOGED JENSEN, Kasper RAND
-
Patent number: 10899846Abstract: Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the secondType: GrantFiled: May 4, 2017Date of Patent: January 26, 2021Assignee: Hoffmann-La Roche Inc.Inventor: Tilman Schlothauer
-
Patent number: 10822402Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: December 5, 2017Date of Patent: November 3, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20200270367Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisiType: ApplicationFiled: May 7, 2020Publication date: August 27, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Ekkehard Moessner, Tilman Schlothauer
-
Patent number: 10683368Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisiType: GrantFiled: May 4, 2017Date of Patent: June 16, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Ekkehard Moessner, Tilman Schlothauer
-
Publication number: 20200172607Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region peptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the firstType: ApplicationFiled: May 24, 2019Publication date: June 4, 2020Inventors: Joerg Thomas Regula, Wolfgang Schaefer, Tilman Schlothauer
-
Publication number: 20200108154Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: ApplicationFiled: August 28, 2019Publication date: April 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jen FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK